The Science Series: ADCs and radiopharmaceuticals

Antibody-drug conjugates (ADCs) are revolutionising targeted therapy, particular for cancer, by harnessing the specificity of antibodies to deliver drugs directly to target cells. There is also currently a lot of attention on radiopharmaceuticals, which pair radioactive particles with antibodies or other targeted carrier molecules, and have uses in diagnostic imaging as well as therapeutics.

In this session, Bristows will explore the science behind ADCs and radiopharmaceuticals, and examine the legal considerations relevant to these technologies.

Meet our speakers

Claire Phipps-Jones, Of Counsel, Bristows

Louisa Jacobs, Senior Associate, Bristows

Jamie Hatzel, Associate, Bristows (Legal considerations)